@article{8b6d872809ff4b95adf559edd7438243,
title = "No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma",
abstract = "The response to treatment varies among patients with multiple myeloma and markers for prediction of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation of bortezomib, is dependent on cytochrome P450 metabolism. We explored the potential influence of different polymorphisms in the CYP enzymes on the outcome of treatment.",
keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Aryl Hydrocarbon Hydroxylases, Boronic Acids, Cyclophosphamide, Cytochrome P-450 CYP2D6, DNA, Neoplasm, Female, Follow-Up Studies, Genotype, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Phenotype, Polymerase Chain Reaction, Polymorphism, Single Nucleotide, Prognosis, Pyrazines, Retrospective Studies, Survival Rate, Thalidomide",
author = "Vangsted, {Annette Juul} and Karen S{\o}eby and Klausen, {Tobias W} and Niels Abildgaard and Andersen, {Niels F} and Peter Gimsing and Henrik Gregersen and Ulla Vogel and Thomas Werge and Rasmussen, {Henrik B}",
year = "2010",
month = jan,
day = "1",
doi = "10.1186/1471-2407-10-404",
language = "English",
volume = "10",
pages = "404",
journal = "B M C Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
}